We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
By Denise Roland
Shire PLC (SHP.LN)said earnings and revenue climbed in the first quarter thanks to strong sales of several rare disease medicines and its blockbuster pill for attention-deficit hyperactivity disorder, or ADHD.
The Dublin-based drug maker said net income rose 2% to $419 million in the three months to March 31, from $410 million a year earlier. Revenue climbed 15% to $1.71 billion from $1.49 billion last year. Analysts expected net income of $487 million and revenue of $1.7 billion.
Non GAAP operating income, a measure which strips out one-time gains or impairments, increased 17% to $797 million.
The strong dollar cut into Shire's results. Stripping out the effect of currency movements, revenue increased 17% and non GAAP operating income rose 16%.
Contact Denise Roland at denise.roland@wsj.com
(END) Dow Jones Newswires
April 29, 2016 07:43 ET (11:43 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
